Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03517449
Title Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Eisai Inc.
Indications

endometrial carcinoma

Therapies

Lenvatinib + Pembrolizumab

Paclitaxel

Doxorubicin

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.